(Information sent by the signing company)
Endoron is one of 75 companies selected from nearly 1,000 applicants for the European EIC Accelerator program. The funds will allow the company to accelerate the development of its unique endovascular fixation solution for complete sealing and stability of endografts used for the treatment of abdominal aortic aneurysms.
Endoron’s technology, Aortoseal®, was developed to overcome the challenges associated with the sealing and fixation of endografts used for minimally invasive abdominal aortic aneurysm (AAA) repair in difficult aortic anatomies, while avoiding highly invasive, high-risk open surgery. mortality that is still used in these cases. Aortoseal® is intended to provide long-term durability to endovascular aneurysm repairs (EVAR), thanks to its unique stapling mechanism. This grant will support the expansion and clinical evaluation of the Aortoseal® implant, necessary to bring this unique technology to 4 million patients diagnosed with AAA who could benefit from a minimally invasive treatment approach. Ronit Harpaz, Co-Founder and CEO of Endoron, commented: “We are delighted that the European Commission has selected Endoron after a highly selective process. The support of the EIC program validates our technology and approach, recognizing the strong value created and milestones achieved in the last 30 months This grant will help accelerate the development and clinical validation of our Aortoseal® implant, allowing a maximum of patients who AAA sufferers benefit from this minimally invasive approach, which has the potential to e become the new standard of care.”Endoron is one of 75 companies awarded funding during the latest round of the program, which involved nearly 1,000 applicants.
ContactContact Name: Ronit HarpazContact Description: General Manager, Endoron Medical
